Amivantamab

MCE 國際站：Amivantamab

CAS：2171511-58-1

品牌：MedChemExpress (MCE)

存儲條件：Please store the product under the recommended conditions in the Certificate of Analysis.

生物活性：Amivantamab (JNJ-61186372) 是一種人源 EGFR-MET 雙特異性抗體，具有免疫抗癌活性。Amivantamab 可以抑制配體結(jié)合，促進受體-抗體復(fù)合物的內(nèi)吞作用和降解，并誘導(dǎo)巨噬細胞的 Fc 依賴性胞吞作用和自然殺傷細胞的抗體依賴性細胞毒性。

體外：Amivantamab (JNJ-61186372)(0.05-1 mg/mL) 導(dǎo)致 Ba/F3 細胞活力顯著且劑量依賴性降低，EGFR 下游信號通路磷酸化 EGFR (pEGFR)、磷酸化 AKT (pAKT)、磷酸化 ERK (pERK) 和磷酸化 S6 (pS6) 也顯著降低[2]。 Amivantamab (JNJ-61186372) 可以通過下調(diào) EGFR 和 MET 信號通路在具有 EGFR Exon20ins 突變的 NSCLC 患者來源的癌細胞中具有有效的抗腫瘤活性[2]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

體內(nèi)：Amivantamab (JNJ-61186372) (i.p, 30 mg/kg, twice a week, 15 days) 可以有效減小在雌性無胸腺 BALB-c/nu 小鼠的 EGFR Exon20ins 突變的 NSCLC 異種移植模型中的腫瘤體積，具有體內(nèi)抗腫瘤作用[2]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Clinical Trial

銷售產(chǎn)品：Pyrithione  | 2-Hydroxybutyric acid  | L-Glutamic acid  | Trimethylamine N-oxide  | Ociperlimab  | Procyanidin B2  | IPR-803  | Micafungin (sodium)  | DCLK1-IN-1  | Vitamin D3

研究領(lǐng)域：JAK/STAT Signaling  |  Protein Tyrosine Kinase/RTK

作用靶點：EGFR

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides

參考文獻：

[1]. Keunchil Park, et al. Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. J Clin Oncol. 2021 Oct 20;39(30):3391-3402.

[2]. Jiyeon Yun, et al. Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC. Cancer Discov. 2020 Aug;10(8):1194-1209.